✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
LY2606368 is an investigational drug.
There have been 16 clinical trials for LY2606368. The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.
The most common disease conditions in clinical trials are Neoplasms, Central Nervous System Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).
There are three US patents protecting this investigational drug and seventy international patents.
Recent Clinical Trials for LY2606368
|Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors||Eli Lilly and Company||Phase 1|
|Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors||St. Jude Children's Research Hospital||Phase 1|
|Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial||Eli Lilly and Company||Phase 1|
Top disease conditions for LY2606368
Top clinical trial sponsors for LY2606368
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LY2606368||See Plans and Pricing||5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate||Eli Lilly and Company (Indianapolis, IN)||See Plans and Pricing|
|LY2606368||See Plans and Pricing||Targeted therapeutics||MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)||See Plans and Pricing|
|LY2606368||See Plans and Pricing||5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts||Eli Lilly and Company (Indianapolis, IN)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|LY2606368||Argentina||AR106772||2035-12-07||See Plans and Pricing|
|LY2606368||Australia||AU2016367041||2035-12-07||See Plans and Pricing|
|LY2606368||Brazil||BR112018008398||2035-12-07||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|